• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Quintiles seeks to refinance debt

Quintiles seeks to refinance debt

March 9, 2011
CenterWatch Staff

Quintiles, looking to take advantage of more favorable terms from banks, is seeking to refinance $1.7 billion in debt and bolster its capital in the process, according to a report in the Triangle Business Journal.

The company wants to sell about $2.4 billion in debt. It would use $1.7 billion to retire an existing debt with higher rates and use the remaining money for acquisitions, partnerships, dividend payouts and share repurchases.

The new financing, if completed, would not change the ownership structure of Quintiles, said company spokesman Phil Bridges. Private equity players TPG Capital and Bain Capital bought One Equity Partners’ majority stake in Quintiles for more than $3 billion in 2008. Among other investors in Quintiles are company founder and Chairman Dennis Gillings and companies 3i, Aisling Capital and Temasek Holdings of Singapore.

In addition to refinancing existing debt, the new credit facilities would provide Quintiles with $700 million in fresh capital the company envisions using for corporate purposes, including acquisitions and strategic alliances, or partnerships with other companies – one of Quintiles’ preferred methods of doing business.

Durham, N.C.-based Quintiles is best known for being the world’s largest provider of clinical trials services, but it also enters into a variety of partnerships with pharmaceutical and other companies in various areas of drug development and sales. For example, Quintiles will provide sales teams for drug makers looking to move product.

Bridges could not identify specific acquisition or partnership targets but confirmed that Asia remains a focus for Quintiles, which has 1,500 employees in the Triangle and more than 20,000 worldwide.

“Asia is definitely a continued focus,” Bridges said. “It is a growing area in terms of population, spending on health care and the clinical trials market.”

Speculation has been rife about Quintiles executing an initial public offering in the near future as the company’s private equity owners seek a return on investment. The fresh capital provided by the debt refinancing would seem to address some of those concerns and possibly push back an IPO. “There are no (IPO) plans at this time,” Bridges said.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing